SpyGlass Pharma (SGP.US) Surges Over 43% in Market Debut on Nasdaq

On Friday, SpyGlass Pharma (SGP.US) debuted on the US stock market with its opening share price surging over 43% to $23, compared to the IPO price of $16. SpyGlass Pharma is a clinical-stage biotechnology company focused on developing sustained drug delivery systems for chronic ocular diseases, aiming to improve patients' vision and quality of life through longer-lasting and sustainable treatment solutions. Its core R&D product includes a system that combines a drug delivery pad with an intraocular lens for treating chronic eye conditions like open-angle glaucoma or ocular hypertension. Such treatments aim to enhance efficacy and patient compliance, offering potential advantages over traditional daily eye drop regimens.